Peptidic degron for IMiD-induced degradation of heterologous proteins.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
12 02 2019
Historique:
pubmed: 27 1 2019
medline: 25 6 2019
entrez: 27 1 2019
Statut: ppublish

Résumé

Current systems for modulating the abundance of proteins of interest in living cells are powerful tools for studying protein function but differ in terms of their complexity and ease of use. Moreover, no one system is ideal for all applications, and the best system for a given protein of interest must often be determined empirically. The thalidomide-like molecules (collectively called the IMiDs) bind to the ubiquitously expressed cereblon ubiquitin ligase complex and alter its substrate specificity such that it targets the IKZF1 and IKZF3 lymphocyte transcription factors for destruction. Here, we mapped the minimal IMiD-responsive IKZF3 degron and show that this peptidic degron can be used to target heterologous proteins for destruction with IMiDs in a time- and dose-dependent manner in cultured cells grown ex vivo or in vivo.

Identifiants

pubmed: 30683719
pii: 1818109116
doi: 10.1073/pnas.1818109116
pmc: PMC6377458
doi:

Substances chimiques

Ikzf3 protein, mouse 0
Peptides 0
Proteins 0
Trans-Activators 0
Zfpn1a1 protein, mouse 0
Ikaros Transcription Factor 148971-36-2
Thalidomide 4Z8R6ORS6L
Ubiquitin-Protein Ligase Complexes EC 2.3.2.23

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2539-2544

Subventions

Organisme : NCI NIH HHS
ID : P50 CA101942
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA210068
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009172
Pays : United States
Organisme : Howard Hughes Medical Institute
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA006516
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA165962
Pays : United States

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Nature. 2014 Aug 7;512(7512):49-53
pubmed: 25043012
Chem Biol. 2014 Sep 18;21(9):1238-52
pubmed: 25237866
Chem Biol. 2010 Sep 24;17(9):981-8
pubmed: 20851347
Nat Chem Biol. 2017 Jun;13(6):675-680
pubmed: 28437394
Br J Haematol. 2014 Mar;164(6):811-21
pubmed: 24328678
Cell. 2006 Sep 8;126(5):995-1004
pubmed: 16959577
Elife. 2018 Aug 01;7:
pubmed: 30067223
Cell. 2006 Sep 8;126(5):827-9
pubmed: 16959558
Science. 2008 Nov 7;322(5903):918-23
pubmed: 18988847
Nat Chem Biol. 2015 Sep;11(9):637-8
pubmed: 26284670
Science. 2014 Jan 17;343(6168):305-9
pubmed: 24292623
Science. 2017 Apr 28;356(6336):
pubmed: 28302793
Science. 2014 Jan 17;343(6168):301-5
pubmed: 24292625
Chembiochem. 2014 Apr 14;15(6):805-9
pubmed: 24615791
Nature. 2016 Jun 22;535(7611):252-7
pubmed: 27338790
Nat Chem Biol. 2015 Sep;11(9):713-20
pubmed: 26214256
Cancer Cell. 2013 Mar 18;23(3):302-15
pubmed: 23477830
Nat Chem Biol. 2018 May;14(5):431-441
pubmed: 29581585
Blood. 2018 Oct 4;132(14):1535-1544
pubmed: 30064974
Nature. 2015 Jul 9;523(7559):183-188
pubmed: 26131937
Nat Methods. 2009 Dec;6(12):917-22
pubmed: 19915560
Nat Chem Biol. 2011 Jul 03;7(8):531-7
pubmed: 21725303
Cell Rep. 2016 Apr 5;15(1):210-218
pubmed: 27052166
Nature. 2005 Jul 7;436(7047):117-22
pubmed: 16001072
Nat Struct Mol Biol. 2014 Sep;21(9):803-9
pubmed: 25108355
Biotechniques. 2016 Feb 01;60(2):69-74
pubmed: 26842351

Auteurs

Vidyasagar Koduri (V)

Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Womens Hospital, Harvard Medical School, Boston, MA 02215.

Samuel K McBrayer (SK)

Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Womens Hospital, Harvard Medical School, Boston, MA 02215.

Ella Liberzon (E)

Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Womens Hospital, Harvard Medical School, Boston, MA 02215.

Adam C Wang (AC)

Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Womens Hospital, Harvard Medical School, Boston, MA 02215.

Kimberly J Briggs (KJ)

Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Womens Hospital, Harvard Medical School, Boston, MA 02215.

Hyejin Cho (H)

Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Womens Hospital, Harvard Medical School, Boston, MA 02215.

William G Kaelin (WG)

Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Womens Hospital, Harvard Medical School, Boston, MA 02215; william_kaelin@dfci.harvard.edu.
Howard Hughes Medical Institute, Chevy Chase, MD 02185.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH